These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 21776824)

  • 1. A conjugate of gemcitabine with bisphosphonate (Gem/BP) shows potential as a targeted bone-specific therapeutic agent in an animal model of human breast cancer bone metastases.
    El-Mabhouh AA; Nation PN; Abele JT; Riauka T; Postema E; McEwan AJ; Mercer JR
    Oncol Res; 2011; 19(6):287-95. PubMed ID: 21776824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 188Re-labelled gemcitabine/bisphosphonate (Gem/BP): a multi-functional, bone-specific agent as a potential treatment for bone metastases.
    El-Mabhouh AA; Mercer JR
    Eur J Nucl Med Mol Imaging; 2008 Jul; 35(7):1240-8. PubMed ID: 18265977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 99mTc-labeled gemcitabine bisphosphonate drug conjugate as a probe to assess the potential for targeted chemotherapy of metastatic bone cancer.
    El-Mabhouh AA; Angelov CA; Cavell R; Mercer JR
    Nucl Med Biol; 2006 Aug; 33(6):715-22. PubMed ID: 16934690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases.
    Hiraga T; Williams PJ; Mundy GR; Yoneda T
    Cancer Res; 2001 Jun; 61(11):4418-24. PubMed ID: 11389070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemcitabine-Ibandronate Conjugate Enables the Bone-Targeted Combination Therapy in Bone Cancer: Synthesis and Efficacy in Combination with Docetaxel.
    Farrell KB; Zinnen S; Thamm DH; Karpeisky A
    Bioconjug Chem; 2021 Dec; 32(12):2530-2539. PubMed ID: 34779607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced anticancer activity of gemcitabine coupling with conjugated linoleic acid against human breast cancer in vitro and in vivo.
    Tao XM; Wang JC; Wang JB; Feng Q; Gao SY; Zhang LR; Zhang Q
    Eur J Pharm Biopharm; 2012 Oct; 82(2):401-9. PubMed ID: 22728546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs.
    Michigami T; Hiraga T; Williams PJ; Niewolna M; Nishimura R; Mundy GR; Yoneda T
    Breast Cancer Res Treat; 2002 Oct; 75(3):249-58. PubMed ID: 12353814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyaluronan-conjugated liposomes encapsulating gemcitabine for breast cancer stem cells.
    Han NK; Shin DH; Kim JS; Weon KY; Jang CY; Kim JS
    Int J Nanomedicine; 2016; 11():1413-25. PubMed ID: 27103799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Liposomal Gemcitabine, FF-10832, Improves Plasma Stability, Tumor Targeting, and Antitumor Efficacy of Gemcitabine in Pancreatic Cancer Xenograft Models.
    Matsumoto T; Komori T; Yoshino Y; Ioroi T; Kitahashi T; Kitahara H; Ono K; Higuchi T; Sakabe M; Kori H; Kano M; Hori R; Kato Y; Hagiwara S
    Pharm Res; 2021 Jun; 38(6):1093-1106. PubMed ID: 33961188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temperature-sensitive magnetic drug carriers for concurrent gemcitabine chemohyperthermia.
    Kim DH; Guo Y; Zhang Z; Procissi D; Nicolai J; Omary RA; Larson AC
    Adv Healthc Mater; 2014 May; 3(5):714-24. PubMed ID: 24574255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A hyaluronic acid conjugate engineered to synergistically and sequentially deliver gemcitabine and doxorubicin to treat triple negative breast cancer.
    Vogus DR; Evans MA; Pusuluri A; Barajas A; Zhang M; Krishnan V; Nowak M; Menegatti S; Helgeson ME; Squires TM; Mitragotri S
    J Control Release; 2017 Dec; 267():191-202. PubMed ID: 28823957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PEGylated liposomal Gemcitabine: insights into a potential breast cancer therapeutic.
    Papa AL; Sidiqui A; Balasubramanian SU; Sarangi S; Luchette M; Sengupta S; Harfouche R
    Cell Oncol (Dordr); 2013 Dec; 36(6):449-57. PubMed ID: 24081907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The targeting mechanism of DHA ligand and its conjugate with Gemcitabine for the enhanced tumor therapy.
    Li S; Qin J; Tian C; Cao J; Fida G; Wang Z; Chen H; Qian Z; Chen WR; Gu Y
    Oncotarget; 2014 Jun; 5(11):3622-35. PubMed ID: 25004114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice.
    Sasaki A; Boyce BF; Story B; Wright KR; Chapman M; Boyce R; Mundy GR; Yoneda T
    Cancer Res; 1995 Aug; 55(16):3551-7. PubMed ID: 7627963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymer Coated Iron Nanoparticles: Radiolabeling & In vitro Studies.
    Yilmaz S; Ichedef C; Karatay KB; Teksöz S
    Curr Radiopharm; 2021; 14(1):37-45. PubMed ID: 32351192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma.
    Yoneda T; Michigami T; Yi B; Williams PJ; Niewolna M; Hiraga T
    Cancer; 2000 Jun; 88(12 Suppl):2979-88. PubMed ID: 10898341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemcitabine-based polymer-drug conjugate for enhanced anticancer effect in colon cancer.
    Liang TJ; Zhou ZM; Cao YQ; Ma MZ; Wang XJ; Jing K
    Int J Pharm; 2016 Nov; 513(1-2):564-571. PubMed ID: 27613255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted delivery of a peripheral benzodiazepine receptor ligand-gemcitabine conjugate to brain tumors in a xenograft model.
    Guo P; Ma J; Li S; Guo Z; Adams AL; Gallo JM
    Cancer Chemother Pharmacol; 2001 Aug; 48(2):169-76. PubMed ID: 11561783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regression of experimental NIS-expressing breast cancer brain metastases in response to radioiodide/gemcitabine dual therapy.
    Renier C; Do J; Reyna-Neyra A; Foster D; De A; Vogel H; Jeffrey SS; Tse V; Carrasco N; Wapnir I
    Oncotarget; 2016 Aug; 7(34):54811-54824. PubMed ID: 27363025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of a newly developed bisphosphonate, YH529, on osteolytic bone metastases in nude mice.
    Sasaki A; Kitamura K; Alcalde RE; Tanaka T; Suzuki A; Etoh Y; Matsumura T
    Int J Cancer; 1998 Jul; 77(2):279-85. PubMed ID: 9650565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.